Search

In this paper we study a three-dimensional tumor–immune system interaction model consisted of tumor cells, activated T cells, and immune checkpoint inhibitor anti-PD-1. Based on the uncontrollable character of tumor cells in the absence of immune response and treatment, the growth of tumor cells is assumed to be exponential. We discuss the distribution of equilibria qualitatively and study the stability of all possible equilibria with and without anti-PD-1 drug. When no drug is applied, the model has a tumor-free equilibrium and at most one tumorous equilibrium. Biologically, there exists a threshold d T 1 for the death rate d T of T cells: when d T ≥ d T 1 tumor cells will keep growing; when d T < d T 1 tumor cells may be eradicated for some positive initial values and keep growing for some other positive initial values. For the case with anti-PD-1 treatment, the model has at most five tumor-free equilibria and two interior equilibria. Our analysis indicates that there exists a threshold γ A 1 for the intravenous continuous injection γ A : when γ A ≤ γ A 1 the fate of tumor cells is the same as the case with no drug applied; when γ A > γ A 1 the model may exhibit bistable phenomena and periodic orbits. Furthermore, we establish the existence of local Hopf bifurcation around the interior equilibrium and determine the stability of the bifurcating periodic orbits. Our simulations show that the model exhibits a stable periodic orbit which implies the long term coexistence and balance of the tumor and immune system. • Study a tumor–immune system interaction model with an immune checkpoint inhibitor. • Discuss the number and stability of all possible equilibria. • Establish the existence of Hopf bifurcation and the stability of the periodic orbit. • Carry out numerical simulations to illustrate the theoretical results. [ABSTRACT FROM AUTHOR]

The article discusses the research paper "Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)," by Ben Tran, L. Horvath, T. Dorff, et al., which was presented at the 2020 European Society for Medical Oncology Virtual Congress held on September 19-21. Also detailed are the safety and the antitumor activity of AMG 160.